Treatment of Liver Cancer

Por Liu, Chun-Yu, Chen, Kuen-Feng, Chen, Pei-Jer
Publicado no Cold Spring Harb Perspect Med (2015)

Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy

Por Hung, Man-Hsin, Tai, Wei-Tien, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado no World J Gastroenterol (2014)

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

Por Huang, Tzu-Ting, Su, Jung-Chen, Liu, Chun-Yu, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado no Int J Mol Sci (2017)

CIP2A is a target of bortezomib in human triple negative breast cancer cells

Por Tseng, Ling-Ming, Liu, Chun-Yu, Chang, Kung-Chi, Chu, Pei-Yi, Shiau, Chung-Wai, Chen , Kuen-Feng
Publicado em 2012

Nilotinib Induces Autophagy in Hepatocellular Carcinoma through AMPK Activation

Por Yu, Hui-Chuan, Lin, Chen-Si, Tai, Wei-Tien, Liu, Chun-Yu, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado em 2013

Bortezomib Congeners Induce Apoptosis of Hepatocellular Carcinoma via CIP2A Inhibition

Por Hou, Duen-Ren, Huang, Ann-Chi, Shiau, Chung-Wai, Wang, Chun-Yi, Yu, Hui-Chuan, Chen, Kuen-Feng
Publicado no Molecules (2013)

Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells

Por Lin, Yu-Chin, Wu, Meng-Hsuan, Wei, Tzu-Tang, Chuang, Shu-Hui, Chen, Kuen-Feng, Cheng, Ann-Lii, Chen, Ching-Chow
Publicado em 2012

Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome

Por Yu, Hui-Chuan, Hou, Duen-Ren, Liu, Chun-Yu, Lin, Chen-Si, Shiau, Chung-Wai, Cheng, Ann-Lii, Chen, Kuen-Feng
Publicado em 2013

Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells

Por Liu, Chun-Yu, Shiau, Chung-Wai, Kuo, Hsin-Yu, Huang, Hsiang-Po, Chen, Ming-Huang, Tzeng, Cheng-Hwai, Chen, Kuen-Feng
Publicado em 2013

Corrigendum to “Degradation of Epidermal Growth Factor Receptor Mediates Dasatinib-Induced Apoptosis in Head and Neck Squamous Cell Carcinoma Cells” [Neoplasia 14 (2012) 463–475]...

Por Lin, Yu-Chin, Wu, Meng-Hsuan, Wei, Tzu-Tang, Chuang, Shu-Hui, Chen, Kuen-Feng, Cheng, Ann-Lii, Chen, Ching-Chow
Publicado no Neoplasia (2017)

Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinosit...

Por Chen, Kuen-Feng, Yeh, Pei-Yen, Hsu, Chiun, Hsu, Chih-Hung, Lu, Yen-Shen, Hsieh, Hsing-Pang, Chen, Pei-Jer, Cheng, Ann-Lii
Publicado em 2009

Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

Por Liu, Chun-Yu, Tseng, Ling-Ming, Su, Jung-Chen, Chang, Kung-Chi, Chu, Pei-Yi, Tai, Wei-Tien, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado em 2013

Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer()()

Por Fan, Li-Ching, Teng, Hao-Wei, Shiau, Chung-Wai, Tai, Wei-Tien, Hung, Man-Hsin, Yang, Shung-Haur, Jiang, Jeng-Kai, Chen, Kuen-Feng
Publicado no Neoplasia (2015)

Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells

Por Liu, Chun-Yu, Tseng, Ling-Ming, Su, Jung-Chen, Chang, Kung-Chi, Chu, Pei-Yi, Tai, Wei-Tien, Shiau, Chung-Wai, Chen, Kuen-Feng
Publicado no Breast Cancer Res (2017)

Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer

Por Fan, Li-Ching, Teng, Hao-Wei, Shiau, Chung-Wai, Tai, Wei-Tien, Hung, Man-Hsin, Yang, Shung-Haur, Jiang, Jeng-Kai, Chen, Kuen-Feng
Publicado no Oncotarget (2016)

Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody

Por Chen, Kuen-Feng, Chen, Hui-Ling, Shiau, Chung-Wai, Liu, Chun-Yu, Chu, Pei-Yi, Tai, Wei-Tien, Ichikawa, Kimihisa, Chen, Pei-Jer, Cheng, Ann-Lii
Publicado em 2013

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma

Por Hu, Ming-Hung, Chen, Li-Ju, Chen, Yen-Lin, Tsai, Ming-Shen, Shiau, Chung-Wai, Chao, Tzu-I, Liu, Chun-Yu, Kao, Jia-Horng, Chen, Kuen-Feng
Publicado no Oncotarget (2017)

SHP-1 is a target of regorafenib in colorectal cancer

Por Fan, Li-Ching, Teng, Hao-Wei, Shiau, Chung-Wai, Lin, Hang, Hung, Man-Hsin, Chen, Yen-Lin, Huang, Jui-Wen, Tai, Wei-Tien, Yu, Hui-Chuan, Chen, Kuen-Feng
Publicado em 2014

Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance

Por Tseng, Ping-Hui, Lin, Ho-Pi, Zhu, Jiuxiang, Chen, Kuen-Feng, Hade, Erinn M., Young, Donn C., Byrd, John C., Grever, Michael, Johnson, Kara, Druker, Brian J., Chen, Ching-Shih
Publicado em 2005

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells

Por Su, Jung-Chen, Tseng, Ping-Hui, Hsu, Cheng-Yi, Tai, Wei-Tien, Huang, Jui-Wen, Ko, Ching-Huai, Lin, Mai-Wei, Liu, Chun-Yu, Chen, Kuen-Feng, Shiau, Chung-Wai
Publicado em 2014